La presente publicación describe la evidencia científica disponible sobre la efectividad del uso de mascarillas o respiradores en la prevención y control de infecciones respiratorias virales incluido COVID-19 a nivel comunitario y hospitalario. Se identificaron 778 estudios publicados hasta abril... de 2020 como parte de la búsqueda sistemática de evidencias (320 población general y 452 personal de salud). Siete estudios fueron seleccionados para responder a las preguntas de investigación de los cuales cinco fueron ensayos clínicos respecto al subgrupo de población general y una revisión sistemática y un ensayo clínico respecto al subgrupo de personal de salud.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
La presente publicación describe la evidencia científica disponible sobre la precisión diagnóstica de las pruebas rápidas de detección de antígenos para SARS-COV-2. El conocimiento de las pruebas diagnósticas para el coronavirus del síndrome respiratorio agudo grave 2 (SARS-COV-2) sigue evo...lucionando, y una comprensión clara de la naturaleza de las pruebas y la interpretación de sus hallazgos es importante. Este punto de vista describe cómo interpretar 2 tipos de pruebas diagnósticas comúnmente en uso para las infecciones SARS-COV-2: reacción en cadena de polimerasa con transcriptasa reversa (RT-PCR) y ensayo por inmunoabsorción ligado a enzimas IgM e IgG (ELISA)— y cómo los resultados pueden variar con el tiempo.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
This document aims to provide guidance to countries in the identification of priority areas
for intervention as part of the Situational Analysis of their National Cholera Control or
Elimination Plans (NCPs).
Le présent document vise à fournir des indications aux pays pour identifier les zones
d’intervention prioritaires dans le cadre de l’analyse de la situation prévue dans leur plan
national de contrôle et d’élimination du choléra (PNC).
Polio Bulletin
2024 Issue No. 1 - Week 1 (as of 2 January 2024)
Africa is experiencing an increasing burden of cardiac arrhythmias. Unfortunately, the expanding need for appropriate care remains largely unmet because of inadequate funding, shortage of essential medical expertise, and the high cost of diagnostic equipment and treatment modalities. Thus, patients ...receive suboptimal care. A total of 5 of 34 countries (15%) in Sub-Saharan Africa (SSA) lack a single trained cardiologist to provide basic cardiac care. One-third of the SSA countries do not have a single pacemaker center, and more than one-half do not have a coronary catheterization laboratory. Only South Africa and several North African countries provide complete services for cardiac arrhythmias, leaving more than hundreds of millions of people in SSA without access to arrhythmia care considered standard in other parts of the world. Key strategies to improve arrhythmia care in Africa include greater government health care funding, increased emphasis on personnel training through fellowship programs, and greater focus on preventive care.
more
Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani...mals to humans.
Mpox is a viral illness caused by the monkeypox virus (MPXV). It can cause a painful rash, enlarged lymph nodes and fever. Most people fully recover, but some get very sick. The virus transmits from person to person through close, including sexual, contact. It also has animal reservoirs in east, central and west Africa, where spillovers from animals to humans can occasionally occur, sparking further outbreaks.
There are two different clades of the virus: clade I and clade II. Clade I outbreaks are deadlier than clade II outbreaks.
A major emergence of mpox linked to clade II began in 2017, and since 2022, has spread to all regions of the world. Between July 2022 and May 2023, the outbreak was declared a Public Health Emergency of International Concern. While that outbreak has largely subsided, cases and deaths continue to be reported today, illustrating that low-level transmission continues around the world.
Currently, there is also a major outbreak of clade I virus in the Democratic Republic of the Congo (DRC), where cases have been on the rise for decades. Since the beginning of the year, over 6500 cases and 345 deaths have been reported in the DRC. Almost half of these are among children under the age of 15 years.
The Strategic framework for enhancing prevention and control of mpox (2024–2027) provides a roadmap for health authorities, communities, and stakeholders worldwide to control mpox outbreaks in every context, advance mpox research and access to countermeasures, and to minimize zoonotic transmission.
more
Qu'est-ce que la mpox (variole du singe) ?
Download (419.34 KB)
On 14 August 2024, the Director-General of the World Health Organization (WHO) determined that the resurgence of Mpox in the Democratic Republic of Congo (DRC) and a growing number of countries in Africa constitutes a Public Health Emergency of International Concern (PHEIC). Te...mporary recommendations are being developed with input from the International Health Regulations Emergency Committee and will be available in the coming days.
more
Given the circulation of the variant of clade I of mpox virus (MPXV) in the African Region, which is associated in the African Region with sustained transmission and the occurrence of cases in a wider range of age groups, including children, the Pan American Health Organization/World Health Organiza...tion (PAHO/WHO) encourages Member States to remain vigilant to the possibility of introduction of this variant in the Americas, and to continue their surveillance efforts, including genomic sequencing of detected cases, with special emphasis on high-risk groups.
more
In the Region of the Americas, as of 24 February 2023 (16:00 EST), there are a total of 58,578 confirmed cases of mpox (Table 1, Figure 2) were reported from 31 countries and territories, including 76 deaths in: United States of America (34), Brazil (15), Peru (15), Mexico (4), Chile (2), Ecuador (3...), Argentina (2), and Cuba (1), reported from 31 (Table 1, Annex 1, Figure 3). In the last 4 weeks (28 January – 24 February 2023), 607 additional mpox cases were reported from 16 countries and territories, including 9 deaths in Ecuador (1) and United States (8). Eight countries in the Region account for 97% of confirmed cases: United States of America, Brazil, Colombia, Mexico, Peru, Canada, Chile, and Argentina – listed by total number of cases in decrease order (Figure 4). The number of new weekly reported cases in EW 7 compared to EW 6 of 2023 (% variation) decreased by 55%.
more
Bas Uele, Equateur, Haut Uele, Ituri, Kasai, Kasai Central, Kasai Oriental, Kinshasa, Kongo Central, Kwango, Kwilu, Lomami, Lualaba,
Maindombe, Maniema, Mongala, Nord-Ubangi, Nord-Kivu, Sankuru, Sud-Kivu, Sud-Ubangi, Tshopo et Tshuapa